The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function
Open accessAbstract
Glioblastoma multiforme (GBM) is one of the most common encephalic malignant tumors. Due to a high recurrence rate and a lack of effective treatments, the average survival rate remains low. Temozolomide (TMZ), a class of alkylating agent, is widely used as a first-line therapeutic drug during the adjuvant treatment for GBM patients. However, most patients exhibit a palpable resistance to TMZ treatment. Additionally, the underlying mechanism remains to be clarified. In this study, glutathione (GSH) and reactive oxygen species (ROS) levels were found to be closely associated with the sensitivity of GBM cells to TMZ. We also found that TMZ markedly induced xCT, the subunit of glutamate/cystine transporter system xc- expression, which together with the GSH synthesis was increased while the TMZ-inducible ROS level was decreased in GBM cells. In addition, the cystathionine γ-lyase (CTH) acivity, a key enzyme in the transsulfuration pathway was enhanced by TMZ, which insured a cysteine supply and GSH synthesis in a compensatory manner when xCT was blocked. Thus, the individual inhibition of xCT by siRNA and a pharmacological inhibitor (sulfasalazine) only partially inhibited GSH synthesis and moderately enhanced the GBM cell sensitivity to TMZ. However, the TMZ‑induced cytotoxicity was markedly increased along with a marked decrease in GSH levels as result of co-treatment with erastin, which inhibited cysteine uptake from xCT transporter and suppressed CTH activity, leading to impaired transformation from methionine to cysteine. In conclusion, to GBM therapy with a drug combination of TMZ and erastin may be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842
Lu, S. C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.09.008 · Cited by 2,166
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Sato, H., Tamba, M., Ishii, T., & Bannai, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11455 · Cited by 1,109
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640
Conrad, M., & Sato, H. (2012) · Amino Acids · doi:10.1007/s00726-011-0867-5 · Cited by 598
Sasaki, H., Sato, H., Kuriyama-Matsumura, K., Sato, K., Maebara, K., Wang, H., Tamba, M., Itoh, K., Yamamoto, M., & Bannai, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208704200 · Cited by 542
Molecular targets of glioma invasion
Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., & Berens, M. E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6342-5 · Cited by 387
Burnet, N. G., Jefferies, S. J., Benson, R. J., Hunt, D. P., & Treasure, F. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602321 · Cited by 366
The transsulfuration pathway: a source of cysteine for glutathione in astrocytes
McBean, G. J. (2012) · Amino Acids · doi:10.1007/s00726-011-0864-8 · Cited by 244
Lin, C.-J., Lee, C.-C., Shih, Y.-L., Lin, T.-Y., Wang, S.-H., Lin, Y.-F., & Shih, C.-M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.487 · Cited by 225
Ye, P., Mimura, J., Okada, T., Sato, H., Liu, T., Maruyama, A., Ohyama, C., & Itoh, K. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00221-14 · Cited by 208
Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H., Sohda, S., Hamada, H., Yoshikawa, H., Kondo, T., & Bannai, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600786 · Cited by 191
Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., Onishi, N., Masuko, T., Yoshizawa, K., Kawashiri, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3609-t · Cited by 191
O6‐alkylguanine‐DNA alkyltransferase: Role in carcinogenesis and chemotherapy
Margison, G. P., & Santibáñez‐Koref, M. F. (2002) · BioEssays · doi:10.1002/bies.10063 · Cited by 189
Robe, P. A., Martin, D. H., Nguyen-Khac, M. T., Artesi, M., Deprez, M., Albert, A., Vanbelle, S., Califice, S., Bredel, M., & Bours, V. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-372 · Cited by 186
Manna, P., & Jain, S. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407833 · Cited by 168
Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway
Chen, R.-S., Song, Y.-M., Zhou, Z.-Y., Tong, T., Li, Y., Fu, M., Guo, X.-L., Dong, L.-J., He, X., Qiao, H.-X., et al. (2009) · Oncogene · doi:10.1038/onc.2008.414 · Cited by 164
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
Gunther, W. C., Pawlak, E., Damasceno, R. S., Arnold, H., & Terzis, A. J. A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600711 · Cited by 163
Yang, G., Cao, K., Wu, L., & Wang, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408997200 · Cited by 159
Multifaceted resistance of gliomas to temozolomide.
Bocangel, D., Finkelstein, S. D., Schold, S. C., Bhakat, K. K., MITRA, S. P., & Kokkinakis, D. M. (2002) · PubMed · Cited by 135
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma
Guo, W., Zhao, Y., Zhang, Z., Tan, N., Zhao, F., Ge, C., Liang, L., Jia, D., Chen, T., Yao, M., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.024 · Cited by 134
Toyoda, M., Kaira, K., Ohshima, Y., Ishioka, N. S., Shino, M., Sakakura, K., Takayasu, Y., Takahashi, K., Tominaga, H., Oriuchi, N., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.178 · Cited by 133
Integrated Stress Response Modulates Cellular Redox State via Induction of Cystathionine γ-Lyase
Dickhout, J. G., Carlisle, R. E., Jerome, D. E., Mohammed-Ali, Z., Jiang, H., Yang, G., Mani, S., Garg, S. K., Banerjee, R., Kaufman, R. J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304576 · Cited by 129
Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy
Doxsee, D. W., Gout, P. W., Kurita, T., Lo, M., Buckley, A. R., Wang, Y., Xue, H., Karp, C. M., Cutz, J., Cunha, G. R., et al. (2006) · The Prostate · doi:10.1002/pros.20508 · Cited by 124
Ehren, J. L., & Maher, P. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.010 · Cited by 86
Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor‐κB
Chung, W. J., & Sontheimer, H. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06129.x · Cited by 84
Schneider, M., Wortmann, M., Mandal, P. K., Arpornchayanon, W., Jannasch, K., Alves, F., Strieth, S., Conrad, M., & Beck, H. (2010) · Neoplasia · doi:10.1593/neo.91782 · Cited by 79
Hottinger, A. F., Aïssa, A. B., Espeli, V. G., Squiban, D., Dunkel, N., Vargas, M. I., Hundsberger, T., Mach, N., Schaller, K., Weber, D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.209 · Cited by 72
She, X., Yu, Z., Cui, Y., Lei, Q., Wang, Z., Xu, G., Xiang, J., Wu, M., & Li, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3318 · Cited by 65
Bartels, U. K., Wolff, J. E. A., Gore, L., Dunkel, I. J., Gilheeney, S. W., Allen, J. C., Goldman, S., Yalon, M., Packer, R. J., Korones, D. N., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou091 · Cited by 62
Dai, L., Cao, Y., Chen, Y., Parsons, C. H., & Qin, Z. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-30 · Cited by 61
Kandil, S. B., Brennan, L., & McBean, G. J. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.01.004 · Cited by 56
Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma
Takeuchi, S., Wada, K., Nagatani, K., Otani, N., Osada, H., & Nawashiro, H. (2014) · Neurology India · doi:10.4103/0028-3886.128280 · Cited by 55
Transsulfuration is an active pathway for cysteine biosynthesis in Trypanosoma rangeli
Romero, I., Téllez, J., Yamanaka, L. E., Steindel, M., Romanha, Á. J., & Grisard, E. C. (2014) · Parasites & Vectors · doi:10.1186/1756-3305-7-197 · Cited by 36
Ras Signaling is Involved in the Expression of Fas-L in Glioma
Yang, B.-C., Wang, Y.-S., Liu, H., & Lin, S.-J. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780058 · Cited by 18
Giordana, L., Mantilla, B. S., Santana, M., Silber, A. M., & Nowicki, C. (2014) · Journal of Eukaryotic Microbiology · doi:10.1111/jeu.12100 · Cited by 12
Cited by
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
Recent Progress in Ferroptosis Inducers for Cancer Therapy
Liang, C., Zhang, X., Yang, M., & Dong, X. (2019) · Advanced Materials · doi:10.1002/adma.201904197 · Cited by 1,569
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model
Zhang, Y., Tan, H., Daniels, J. D., Zandkarimi, F., Liu, H., Brown, L. M., Uchida, K., O'Connor, O. A., & Stockwell, B. R. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.01.008 · Cited by 721
Metadata
- Authors
- CHEN, L., LI, X., LIU, L., YU, B., XUE, Y., & LIU, Y.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2015-01-13
- Volume
- 33
- Issue
- 3
- Pages
- 1465-1474
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W2001764001
- Cited by
- 279
- References
- 43
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.